论文部分内容阅读
目的 为探讨澳大利亚生产的紫杉醇安素泰对恶性肿瘤的疗效。方法 从1996年6月至1997年6月采用安素泰单药和联合用药治疗恶性肿瘤26例。男性8例,女性18例;中位年龄54岁;初治者11例,复治者15例;Ⅲ期6例,Ⅳ期20例。安素泰+顺铂治疗非小细胞肺癌11例,PR2例,有效率18.2％。单药安素泰治疗乳腺癌7例,PR6例(85.7％),安素泰+阿霉素或顺铂治疗乳癌8例,PR5例(62.5％)。本组总有效率50.0％(13/26)。结果 安素泰对乳腺癌疗效较优,对非小细胞肺癌也有一定疗效,毒性可为患者所耐受。结论 安素泰是一个有前途的新药。
Objective To investigate the efficacy of paclitaxel benzoate produced in Australia on malignant tumors. METHODS: From June 1996 to June 1997, 26 cases of malignant tumors were treated with altux and single drugs. There were 8 males and 18 females; the median age was 54 years; 11 were newly diagnosed and 15 were retreated; 6 were in stage III and 20 in stage IV. Ansutamide + cisplatin treatment of 11 cases of non-small cell lung cancer, PR2 cases, an effective rate of 18.2%. Single-agent Ansett has been used to treat 7 cases of breast cancer, 6 cases of PR (85.7%), 8 cases of breast cancer treated with escutar and adriamycin or cisplatin, and 5 cases of PR (62.5%). The total efficiency of this group is 50.0% (13/26). Results Ansutamide has a superior curative effect on breast cancer, and it also has a certain effect on non-small cell lung cancer. Toxicity can be tolerated by patients. Conclusion Ansutamide is a promising new drug.